Sr. Scientist @ Regeneron | Biotechnology R&D & Scientific AI | Founder, “Data‑Rich, Insight‑Poor?” | Science‑first forum on the epistemic and ethical limits of biological data and human‑centred technology
19h •
Following
Aging biology has never been more measured—or more confusing.
We can now track thousands of markers across virtually every tissue.
Methylation clocks tick, single-cell clusters bloom, plasma proteins spike and fall. And yet, most “rejuvenation” stories still boil down to: a few signatures move, and we are asked to believe tissues are younger.
The new work on mesenchymal drift (MD) cuts through that noise.
It reframes aging as a directional loss of cell identity toward mesenchymal, fibrotic states—a trajectory you can measure across >40 human tissues and ~20 diseases, and that tracks with progression, organ failure, and mortality. Instead of asking “which hallmark did we hit?”, MD asks:
Are epithelial, endothelial, and stromal identities holding, or drifting?
Do our interventions actually push cells back toward lineage-stable attractors—or just quiet a few downstream markers?
For fibrosis and longevity programs, this is a different standard of evidence. Moving a clock is interesting. Reversing mesenchymal drift is existential for the tissue.
If you’re building or evaluating aging therapeutics, the uncomfortable question is:
Are you optimizing around convenient readouts, or around the state variable that decides whether organs fail?